Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 8254675, 6 pages
http://dx.doi.org/10.1155/2016/8254675
Research Article

The Relationship between Serum Endocan Levels and Depression in Alzheimer’s Disease

1Department of Psychiatry, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 200-704, Republic of Korea
2Institute for Skeletal Aging, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 200-704, Republic of Korea

Received 17 November 2015; Accepted 24 December 2015

Academic Editor: George Perry

Copyright © 2016 Kyung Hee Yoon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. H. Vagnucci Jr. and W. W. Li, “Alzheimer's disease and angiogenesis,” The Lancet, vol. 361, no. 9357, pp. 605–608, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. D. L. Dickstein, J. Walsh, H. Brautigam, S. D. Stockton Jr., S. Gandy, and P. R. Hof, “Role of vascular risk factors and vascular dysfunction in Alzheimer's disease,” Mount Sinai Journal of Medicine, vol. 77, no. 1, pp. 82–102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Tarkowski, R. Issa, M. Sjögren et al., “Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer's disease and vascular dementia,” Neurobiology of Aging, vol. 23, no. 2, pp. 237–243, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Mateo, J. Llorca, J. Infante et al., “Low serum VEGF levels are associated with Alzheimer's disease,” Acta Neurologica Scandinavica, vol. 116, no. 1, pp. 56–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. N. Kim and D. H. Kim, “Decreased serum angiogenin level in Alzheimer's disease,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 38, no. 2, pp. 116–120, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Jung, S. Kim, K. Yoon et al., “The effect of depression on serum VEGF level in Alzheimer’s disease,” Disease Markers, vol. 2015, Article ID 742612, 6 pages, 2015. View at Publisher · View at Google Scholar
  7. E. Rennel, S. Mellberg, A. Dimberg et al., “Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer,” Experimental Cell Research, vol. 313, no. 7, pp. 1285–1294, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Roudnicky, C. Poyet, P. Wild et al., “Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis,” Cancer Research, vol. 73, no. 3, pp. 1097–1106, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Del Toro, C. Prahst, T. Mathivet et al., “Identification and functional analysis of endothelial tip cell–enriched genes,” Blood, vol. 116, no. 19, pp. 4025–4033, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. G. A. Strasser, J. S. Kaminker, and M. Tessier-Lavigne, “Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching,” Blood, vol. 115, no. 24, pp. 5102–5110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L.-Y. Chen, X. Liu, S.-L. Wang, and C.-Y. Qin, “Over-expression of the Endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion,” Journal of International Medical Research, vol. 38, no. 2, pp. 498–510, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. B. D. Grigoriu, F. Depontieu, A. Scherpereel et al., “Endocan expression and relationship with survival in human non-small cell lung cancer,” Clinical Cancer Research, vol. 12, no. 15, pp. 4575–4582, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Leroy, S. Aubert, L. Zini et al., “Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma,” Histopathology, vol. 56, no. 2, pp. 180–187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Liu, L.-H. Zhang, H. Du et al., “Overexpression of endothelial cell specific molecule-1 (ESM-1) in gastric cancer,” Annals of Surgical Oncology, vol. 17, no. 10, pp. 2628–2639, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Scherpereel, T. Gentina, B. Grigoriu et al., “Overexpression of endocan induces tumor formation,” Cancer Research, vol. 63, no. 18, pp. 6084–6089, 2003. View at Google Scholar · View at Scopus
  16. H. Jiang, X. Fu, and Y. Chen, “Serum level of endothelial cell-specific molecule-1 and prognosis of colorectal cancer,” Genetics and Molecular Research, vol. 14, no. 2, pp. 5519–5526, 2015. View at Publisher · View at Google Scholar
  17. M. M. El Behery, M. A. Seksaka, M. A. Ibrahiem, H. S. Saleh, and Y. El Alfy, “Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer,” Archives of Gynecology and Obstetrics, vol. 288, no. 6, pp. 1371–1376, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. I. Yilmaz, D. Siriopol, M. Saglam et al., “Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease,” Kidney International, vol. 86, no. 6, pp. 1213–1220, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Balta, D. P. Mikhailidis, S. Demirkol et al., “Endocan—a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study,” Angiology, vol. 65, no. 9, pp. 773–777, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Balta, D. P. Mikhailidis, S. Demirkol, C. Ozturk, T. Celik, and A. Iyisoy, “Endocan: a novel inflammatory indicator in cardiovascular disease?” Atherosclerosis, vol. 243, no. 1, pp. 339–343, 2015. View at Publisher · View at Google Scholar
  21. M. Kose, S. Emet, T. S. Akpinar et al., “Serum endocan level and the severity of coronary artery disease: a pilot study,” Angiology, vol. 66, no. 8, pp. 727–731, 2015. View at Publisher · View at Google Scholar
  22. S. Balta, D. P. Mikhailidis, S. Demirkol, T. Celik, C. Ozturk, and A. Iyisoy, “Endocan and atherosclerosis,” Angiology, vol. 66, no. 5, p. 490, 2015. View at Publisher · View at Google Scholar
  23. C. Xiong, Z.-W. Zhao, Z.-Y. Chen et al., “Elevated human endothelial cell-specific molecule-1 level and its association with coronary artery disease in patients with hypertension,” Journal of Investigative Medicine, vol. 63, no. 7, pp. 867–870, 2015. View at Publisher · View at Google Scholar
  24. A. Scherpereel, F. Depontieu, B. Grigoriu et al., “Endocan, a new endothelial marker in human sepsis,” Critical Care Medicine, vol. 34, no. 2, pp. 532–537, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Balta, S. Balta, S. Demirkol et al., “Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease,” British Journal of Dermatology, vol. 169, no. 5, pp. 1066–1070, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. I. Balta, S. Balta, O. M. Koryurek et al., “Serum endocan levels as a marker of disease activity in patients with Behçet disease,” Journal of the American Academy of Dermatology, vol. 70, no. 2, pp. 291–296, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. K. F. Rodrigues, N. T. Pietrani, A. A. Bosco et al., “Endocan: a new biomarker associated with inflammation in type 2 diabetes mellitus?” Diabetes/Metabolism Research and Reviews, vol. 31, no. 5, pp. 479–480, 2015. View at Publisher · View at Google Scholar
  28. D. Pauly, S. Hamed, M. Behnes et al., “Endothelial cell-specific molecule–1/endocan: diagnostic and prognostic value in patients suffering from severe sepsis and septic shock,” Journal of Critical Care, vol. 31, no. 1, pp. 68–75, 2016. View at Publisher · View at Google Scholar
  29. J. T. Olin, L. S. Schneider, I. R. Katz et al., “Provisional diagnostic criteria for depression of Alzheimer disease,” The American Journal of Geriatric Psychiatry, vol. 10, no. 2, pp. 125–128, 2002. View at Google Scholar · View at Scopus
  30. D. Y. Lee, K. U. Lee, J. H. Lee et al., “A normative study of the mini-mental state examination in the Korean elderly,” Journal of Korean Neuropsychiatric Association, vol. 41, no. 3, pp. 508–525, 2002. View at Google Scholar
  31. C. P. Hughes, L. Berg, and W. L. Danziger, “A new clinical scale for the staging of dementia,” The British Journal of Psychiatry, vol. 140, no. 6, pp. 566–572, 1982. View at Publisher · View at Google Scholar · View at Scopus
  32. J. N. Bae and M. J. Cho, “Development of the Korean version of the Geriatric Depression Scale and its short form among elderly psychiatric patients,” Journal of Psychosomatic Research, vol. 57, no. 3, pp. 297–305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Dobie and M. Raskind, “Biology in geriatric psychiatry: diagnostic implications,” in Review of Psychiatry, vol. 9, pp. 232–249, American Psychiatric Press, Washington, DC, USA, 1990. View at Google Scholar
  34. I. J. E. Heuser, U. Schweiger, U. Gotthardt et al., “Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects,” The American Journal of Psychiatry, vol. 153, no. 1, pp. 93–99, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Janke, S. Engeli, K. Gorzelniak et al., “Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity,” Hormone and Metabolic Research, vol. 38, no. 1, pp. 28–33, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Lanquillon, J.-C. Krieg, U. Bening-Abu-Shach, and H. Vedder, “Cytokine production and treatment response in major depressive disorder,” Neuropsychopharmacology, vol. 22, no. 4, pp. 370–379, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. O. Mikova, R. Yakimova, E. Bosmans, G. Kenis, and M. Maes, “Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis,” European Neuropsychopharmacology, vol. 11, no. 3, pp. 203–208, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. G. L. Xiong, K. Prybol, S. H. Boyle et al., “Inflammation markers and major depressive disorder in patients with chronic heart failure: results from the sertraline against depression and heart disease in chronic heart failure study,” Psychosomatic Medicine, vol. 77, no. 7, pp. 808–815, 2015. View at Publisher · View at Google Scholar
  39. V. Gabbay, R. G. Klein, C. M. Alonso et al., “Immune system dysregulation in adolescent major depressive disorder,” Journal of Affective Disorders, vol. 115, no. 1-2, pp. 177–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. V. Gabbay, R. G. Klein, L. E. Guttman et al., “A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression,” Journal of Child and Adolescent Psychopharmacology, vol. 19, no. 4, pp. 423–430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. F. M. Schmidt, N. Lichtblau, J. Minkwitz et al., “Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity,” Journal of Psychiatric Research, vol. 55, no. 1, pp. 29–34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. N. M. Simon, K. McNamara, C. W. Chow et al., “A detailed examination of cytokine abnormalities in Major Depressive Disorder,” European Neuropsychopharmacology, vol. 18, no. 3, pp. 230–233, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Lassalle, S. Molet, A. Janin et al., “ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines,” The Journal of Biological Chemistry, vol. 271, no. 34, pp. 20458–20464, 1996. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Bechard, V. Meignin, A. Scherpereel et al., “Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies,” Journal of Vascular Research, vol. 37, no. 5, pp. 417–425, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. K. A. Jellinger and J. Attems, “Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study,” Acta Neuropathologica, vol. 105, no. 1, pp. 14–17, 2003. View at Google Scholar · View at Scopus
  46. B. V. Zlokovic, “Neurovascular mechanisms of Alzheimer's neurodegeneration,” Trends in Neurosciences, vol. 28, no. 4, pp. 202–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Akiyama, S. Barger, S. Barnum et al., “Inflammation and Alzheimer's disease,” Neurobiology of Aging, vol. 21, no. 3, pp. 383–421, 2000. View at Publisher · View at Google Scholar
  48. P. Grammas and R. Ovase, “Inflammatory factors are elevated in brain microvessels in Alzheimer's disease,” Neurobiology of Aging, vol. 22, no. 6, pp. 837–842, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. M. T. Heneka and M. K. O'Banion, “Inflammatory processes in Alzheimer's disease,” Journal of Neuroimmunology, vol. 184, no. 1-2, pp. 69–91, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Wyss-Coray, “Inflammation in Alzheimer disease: driving force, bystander or beneficial response?” Nature Medicine, vol. 12, no. 9, pp. 1005–1015, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. M. A. Rapp, M. Schnaider-Beeri, D. P. Purohit, D. P. Perl, V. Haroutunian, and M. Sano, “Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression,” The American Journal of Geriatric Psychiatry, vol. 16, no. 2, pp. 168–174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Spalletta, C. Caltagirone, P. Girardi, W. Gianni, A. R. Casini, and K. Palmer, “The role of persistent and incident major depression on rate of cognitive deterioration in newly diagnosed Alzheimer's disease patients,” Psychiatry Research, vol. 198, no. 2, pp. 263–268, 2012. View at Publisher · View at Google Scholar · View at Scopus